CoChat

Differential Effects of Oral Estrogen versus Oral Estrogen-Androgen Replacement Therapy on Body Composition in Postmenopausal Women

Dobs, A. S. · 2002 · Journal of Clinical Endocrinology & Metabolism
Cited by 54

The DOI matches its Crossref record.

Abstract

Menopause is associated with decreased lean body mass and increased fat due to aging and declining hormone secretion. Estrogens or estrogen-progestins have been used to alleviate vasomotor symptoms. However, estrogen-androgen (E/A) therapy is also used for vasomotor symptom relief and has been shown to increase lean body mass while decreasing fat mass. The objective of this 16-wk, double-blind, randomized, parallel group clinical trial was to compare esterified estrogen plus methyltestosterone (1.25 mg estrogen + 2.5 mg methyltestosterone/d; E/A group) vs. esterified estrogen alone (1.25 mg/d; E group) on body composition. Forty postmenopausal women (mean age, 57 yr) participated. Compared with estrogen treatment alone, women in the E/A group increased their total lean body mass and reduced their percentage fat for all body parts (P < 0.05). After E/A treatment, there were statistically significant increases in lean body mass by 1.232 kg [0.181 ± 0.004, 0.81 ± 0.057, and 0.24 ± 0.009 kg in the upper body (P = 0.021), trunk (P = 0.001), and lower body (P = 0.047), respectively]. In the E group, the increase was 0.31 ± 0.004, 0.021 ± 0.03, and 0.056 ± 0.05 kg in the upper body, trunk, and lower body, respectively. In the E/A group, body fat was reduced by 0.90 kg (P = 0.18 for the trunk only), and percentage body fat declined by 7.4% (P ≤ 0.05 for all body parts). Lower body strength increased by 23.1 kg (51 lb) in the E/A group vs. only 11 kg (24.25 lb) in the E group (P = 0.002 between groups). A statistically significant increase in weight (2.7 ± 5.1 vs. 0.1 ± 4.6 lb; P < 0.05) was observed in the E/A group compared with the E group. When subjects were given self-reporting questionnaires, more improvement was noted in sexual functioning and quality of life in the E/A group when compared with patients receiving E alone. There were no noteworthy side effects. In conclusion, E/A replacement therapy can improve body composition, lower-body muscle strength, quality of life, and sexual functioning in postmenopausal women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.87.4.1509

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 57

  1. Aloia, 1991, The relationship of menopause to skeletal and muscle mass, Am J Clin Nutr, 53, 1378, 10.1093/ajcn/53.6.1378 · DOI · Paper page
  2. Douchi, 1998, The effect of menopause on regional and total body lean mass, Maturitas, 29, 247, 10.1016/S0378-5122(98)00035-8 · DOI
  3. Guo, 1999, Aging, body composition and lifestyle: the Fels Longitudinal Study, Am J Clin Nutr, 70, 405, 10.1093/ajcn/70.3.405 · DOI · Paper page
  4. Chen, 1997, Fat or lean tissue mass: which one is the major determinant of bone mineral mass in healthy postmenopausal women?, J Bone Miner Res, 12, 144, 10.1359/jbmr.1997.12.1.144 · DOI · Paper page
  5. Tchernof, 1998, Menopause, central body fatness and insulin resistance: effects of hormone replacement therapy, Coron Artery Dis, 9, 503, 10.1097/00019501-199809080-00006 · DOI · Paper page
  6. Lindsay, 1984, The minimum effective dose of estrogen for prevention of postmenopausal bone loss, Obstet Gynecol, 63, 759
  7. Eastell, 1998, Treatment of postmenopausal osteoporosis, N Engl J Med, 338, 736, 10.1056/NEJM199803123381107 · DOI · Paper page
  8. Henderson, 1994, Estrogen replacement therapy in older women: comparisons between Alzheimer’s disease cases and nondemented control subjects, Arch Neurol, 51, 896, 10.1001/archneur.1994.00540210068014 · DOI · Paper page
  9. Grady, 1992, Hormone therapy to prevent disease and prolong life in postmenopausal women, Ann Intern Med, 117, 1016, 10.7326/0003-4819-117-12-1016 · DOI · Paper page
  10. Hassager, 1989, Estrogen/gestagen therapy changes soft tissue body composition in postmenopausal women, Metabolism, 38, 662, 10.1016/0026-0495(89)90104-2 · DOI
  11. Sayegh, 1999, Impact of hormone replacement therapy on body mass and fat compositions of menopausal women: a cross-sectional study, Menopause, 6, 312, 10.1097/00042192-199906040-00007 · DOI
  12. Haarbo, 1991, Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause, Metabolism, 40, 1323, 10.1016/0026-0495(91)90037-W · DOI · Paper page
  13. Aloia, 1995, The influence of menopause and hormonal replacement therapy on body cell mass and body fat mass, Am J Obstet Gynecol, 3, 896, 10.1016/0002-9378(95)90018-7 · DOI
  14. Taaffe, 1995, Maximal muscle strength of elderly women is not influenced by estrogen status, Age Ageing, 24, 329, 10.1093/ageing/24.4.329 · DOI · Paper page
  15. Seeley, 1995, Is postmenopausal estrogen therapy associated with neuromuscular function or falling in elderly women?, Arch Intern Med, 155, 293, 10.1001/archinte.1995.00430030087010 · doi:10.1001/archinte.1995.00430030087010 · Paper page
  16. Hanggi, 1998, Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women, Clin Endocrinol (Oxf), 48, 691, 10.1046/j.1365-2265.1998.00481.x · DOI · Paper page
  17. Adashi, 1994, The climacteric ovary as a functional gonadotropin-driven and androgen-producing gland, Fertil Steril, 62, 20, 10.1016/S0015-0282(16)56810-1 · DOI · Paper page
  18. Vermeulen, 1976, The hormonal activity of the postmenopausal ovary, J Clin Endocrinol Metab, 42, 247, 10.1210/jcem-42-2-247 · DOI · Paper page
  19. Geist, 1941, Androgen therapy in gynecology, JAMA, 2207, 10.1001/jama.1941.02820520003002 · DOI
  20. Brinbeg, 1955, Low-dosage androgen-estrogen therapy in the older age group. Symposium presentation, J Am Geriatr Soc, 3, 656, 10.1111/j.1532-5415.1955.tb00880.x · DOI
  21. Sherwin, 1988, Affective changes with estrogen and androgen replacement therapy in surgically menopausal women, J Affect Disord, 14, 177, 10.1016/0165-0327(88)90061-4 · DOI · Paper page
  22. Sherwin, 1985, Differential symptom response to parenteral estrogen and or androgen administration in surgical menopause, Am J Obstet Gynecol, 2, 153, 10.1016/0002-9378(85)90001-8 · DOI · Paper page
  23. Raisz, 1996, Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women, J Clin Endocrinol Metab, 81, 37
  24. Simon, 1999, Differential effects of estrogen-androgen and estrogen only therapy on vasomotor symptoms, gonadotropin secretion, endogenous androgen biovailability in postmenopausal women, Menopause, 6, 138, 10.1097/00042192-199906020-00011 · DOI · Paper page
  25. Davis, 1995, Testosterone enhances estradiol effects on postmenopausal bone density and sexuality, Mautritas, 21, 227, 10.1016/0378-5122(94)00898-H · DOI · Paper page
  26. Barrett-Connor, 1999, A two-year double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women: effects on bone mineral density, symptoms and lipid profiles, J Reprod Med, 44, 1012
  27. Hassager, 1991, Soft tissue body composition during prevention and treatment of postmenopausal osteoporosis assessed by photon absorptiometry, Dan Med Bull, 38, 380
  28. Aloia, 1981, Changes in body composition following therapy of osteoporosis with methandrostenolone, Metabolism, 30, 1076, 10.1016/0026-0495(81)90050-0 · DOI
  29. Gruber, 1998, Effect of percutaneous androgen replacement therapy on body composition and body weight in postmenopausal women, Maturitas, 29, 253, 10.1016/S0378-5122(98)00031-0 · DOI
  30. Miller, 1998, Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study, J Clin Endocrinol Metab, 83, 2717
  31. Wang, 2000, Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men, J Clin Endocrinol Metab, 85, 2839
  32. de Lorenzo, 1998, Fat free mass by bioelectrical impedance vs dual energy x-ray absorptiometry, Appl Radiat Isot, 49, 739, 10.1016/S0969-8043(97)00099-7 · DOI
  33. Blake, 1997, Technical principals of dual energy x-ray absorptiometry, Semin Nucl Mede, 27, 210, 10.1016/S0001-2998(97)80025-6 · DOI · Paper page
  34. Shizgal, 1990, Validation of measurement of body composition from whole body bioelectric impedance analysis, Infusionstherapie, 17, 64
  35. Jodoin, 1988, Determination of whole body composition from whole body electrical impedance, Surg Forum, 39, 50
  36. Taylor, 1994, Self-report assessment of female sexual function: pyschometric evaluation of Brief Index of Sexual Functioning for Women, Arch Sex Behav, 23, 627, 10.1007/BF01541816 · DOI · Paper page
  37. Garratt, 1995, Measuring sexual functioning in premenopausal women, Brit J Ostet Gynaecol, 102, 311, 10.1111/j.1471-0528.1995.tb09138.x · DOI · Paper page
  38. Sarrel, 1998, Sexual interest and functioning in postmenopausal women: a community-based national survey, Menopause, 5, 262, 10.1097/00042192-199805040-00084 · DOI
  39. Vermeulen, 1999, Testosterone, body composition and aging, J Endocrinol Invest, 22, 110
  40. Nemechek, 2000, Treatment guidelines for HIV-associated wasting, Mayo Clin Proc, 75, 386, 10.4065/75.4.386 · DOI
  41. Lamarche, 1998, Abdominal obesity and its metabolic complications: implications for the risk of ischemic heart disease, Coron Artery Dis, 9, 473, 10.1097/00019501-199809080-00002 · DOI · Paper page
  42. Kannel, 1991, Regional obesity and risk of cardiovascular disease; the Framingham Study, J Clin Epidemiol, 44, 183, 10.1016/0895-4356(91)90265-B · DOI · Paper page
  43. Seo, 1990, Effect of disuse on bone mineral density content, lean mass and fat mass in osteoarthritic patients, J Bone Miner Res, 5, 371
  44. Pietrobelli, 1996, Dual-energy x-ray absorptiometry body composition model: review of physical concepts, Am J Physiol, 271, E941
  45. Pietrobelli, 1998, Dual-energy x-ray absorptiometry: fat estimation errors due to variation in soft tissue hydration, Am J Physiol, 274, E808
  46. Bhasin, 1996, The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men, N Engl J Med, 335, 1, 10.1056/NEJM199607043350101 · DOI · Paper page
  47. Bhasin, 2000, Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels, JAMA, 283, 763, 10.1001/jama.283.6.763 · DOI · Paper page
  48. Phillips, 1997, Safety surveillance of esterified estrogens-methyltestosterone (Estratest and Estratest HS) replacement therapy in the United States, Clin Ther, 19, 1070, 10.1016/S0149-2918(97)80060-4 · DOI
  49. Gitlin, 1999, Liver function in postmenopausal women on estrogen-androgen hormone replacement therapy: a meta-analysis of eight clinical trials, Menopause, 6, 216, 10.1097/00042192-199906030-00007 · DOI
  50. Gelfand, 1997, Androgen and estrogen-androgen hormone replacement therapy: a review of safety literature 1941–1996, Clin Ther, 19, 383, 10.1016/S0149-2918(97)80125-7 · DOI
  51. Pasquali, 1997, Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio Menopause Health Group, Metabolism, 46, 5, 10.1016/S0026-0495(97)90159-1 · DOI · Paper page
  52. Hulley, 1998, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Research Group (HERS), JAMA, 280, 605, 10.1001/jama.280.7.605 · DOI · Paper page
  53. Ansell, 1999, An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program, JAMA, 282, 2051, 10.1001/jama.282.21.2051 · DOI · Paper page
  54. Gotto, 1998, Triglyceride as a risk factor for coronary artery disease, Am J Cardiol, 82, 22, 10.1016/S0002-9149(98)00770-X · DOI · Paper page
  55. Gotto, 1998, Preventing coronary heart disease in women: brief observation from the clinical data, J Womens Health, 7, 195, 10.1089/jwh.1998.7.195 · DOI
  56. Austin, 1999, Epidemiology of hypertriglyceridemia and cardiovascular disease, Am J Cardiol, 83, 13, 10.1016/S0002-9149(99)00209-X · DOI
  57. Sherwin, 1987, The role of androgen in the maintenance of sexual functioning in oophorectomized women, Psychosom Med, 49, 397, 10.1097/00006842-198707000-00009 · DOI · Paper page

Cited by

Metadata

Authors
Dobs, A. S.
Venue
Journal of Clinical Endocrinology & Metabolism
Published
2002-04-01
Volume
87
Issue
4
Pages
1509-1516
ISSN
0021-972X (ISSN-L)
OpenAlex
W4239008288
Cited by
54
References
0
FWCI
4.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.